Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbzena Share News (ABZA)

  • There is currently no data for ABZA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Abzena Says Gilead Advancing Antibody To Further Clinical Trials

Wed, 13th May 2015 07:47

LONDON (Alliance News) - Life sciences company Abzena PLC on Wednesday said US biotechnology company Gilead Sciences is to move the GS-5745 antibody directly into a phase 3 clinical study in gastic cancer in the third quarter of this year.

The antibody uses Abzena's Composite Human Antibody technology. It is currently under evaluation for pancreatic cancer in a phase 1b study also and a phase 2 study for its use in Crohn's disease has also been initiated.

"We are encouraged by the clinical progress that Gilead is making with GS-5745 across a range of indications," said Abzena Chief Executive John Burt.

Shares in Abzena were untraded Wednesday, having last traded at 82.70 pence.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
11 Oct 2018 11:15

Abzena Shares Suspended As Acquisition Becomes Effective (ALLISS)

LONDON (Alliance News) - Abzena PLC shares were suspended from trading on AIM on Thursday as the company's acquisition by Astro BidCo Ltd became effective.The biopharmaceutical firm its

Read more
2 Oct 2018 14:20

Abzena Acquisition By Astro Bidco Gains Shareholder Approval

LONDON (Alliance News) - Biopharmaceutical technology firm Abzena PLC said on Tuesday that at a court meeting and general meeting held earlier, its acquisition by Astro Bidco Ltd was approved by a

Read more
10 Sep 2018 15:46

UK Shareholder Meetings Calendar - Next 7 Days

Tuesday 11 SeptemberAshtead GroupBilbyCohortMulberry 12 Direct Oil & UK 13 14 UK

Read more
16 Aug 2018 10:37

WINNERS & LOSERS SUMMARY: Acquisition Puts On The Beach On Buying Wave

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - down 2.6%, Legal & down down 0.7%,

Read more
16 Aug 2018 10:18

Abzena agrees to be taken over by US private equity firm WCAS

(Sharecast News) - Abzena has agreed to be taken over by US private equity firm WCAS in a £34.4m deal.

Read more
16 Aug 2018 10:09

Abzena To Go Private As It Agrees GBP34 Million Takeover By Astro

LONDON (Alliance News) - Shares in biopharmaceutical technology firm Abzena PLC rocketed Thursday after agreed to a takeover valuing the firm at around GBP34.4 million.Astro Bidco Ltd, a up

Read more
14 Jun 2018 11:56

Shares In Abzena Fall As It Seeks To Monetise Royalty-Bearing Products

LONDON (Alliance News) - Abzena PLC on Thursday said it has entered into a non-binding heads of terms agreement with an unconnected third party as it requires additional funding to support its in

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
20 Jan 2017 10:42

WINNERS & LOSERS SUMMARY: Shares Of Upbeat Synthomer Hit Record High

Read more
20 Jan 2017 10:29

Abzena signs licensing agreement for 'ThioBridge' technology

(ShareCast News) - Life sciences group Abzena announced on Friday that it has signed a licensing agreement with an unnamed San Diego-based biopharmaceutical company for its site-specific 'ThioBridge' antibody drug conjugate linker technology. The AIM-traded company said 'ThioBridge' links antibodies

Read more
20 Jan 2017 08:33

Abzena Shares Jump On ThioBridge Licensing Agreement In US

Read more
22 Dec 2016 14:20

Abzena inks licence agreement with Trieza Therapeutics

(ShareCast News) - Life-sciences group Abzena has inked a licence agreement with start-up biotechnology company Trieza Therapeutics. US-based Trieza specialises in the discovery and development of immunomodulatory oncolytic viruses. Abzena has granted Trieza an exclusive licence to an undisclosed a

Read more
2 Nov 2016 14:11

Abzena shares plunge as Gilead drops simtuzumab

(ShareCast News) - Life sciences group Abzena noted on Wednesday that during Gilead Sciences' announcement of third quarter earnings on 1 November, it stated that no further development of simtuzumab will be pursued. The AIM-traded firm also noted that GS-5745 will not be progressed further by Gilea

Read more
21 Oct 2016 13:47

Abzena notes progress with Composite Human Antibody tech

(ShareCast News) - Life sciences group Abzena noted on Friday that Gilead Sciences has announced top line Phase II clinical study results of its product, GS-4997 (selonsertib) in combination with the investigational monoclonal antibody, simtuzumab (SIM) or SIM alone, in patients with non-alcoholic s

Read more
6 Sep 2016 15:07

UK Shareholder Meetings Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.